ATLASVirtus Biotech ETF (BBP): outlook, holdings and fees
Virtus Biotech ETF (BBP) is an exchange-traded fund and is managed by Virtus. The expense ratio is 0.77% and the yield is 0.00%. The ten largest holdings are 28% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on BBP
| Last price | $102.35 (-1.8%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 51% |
| Likely 1-month range (50%) | $97.60 – $107.83 |
| Normal 1-day range (±1σ) | ±1.7% |
| Distribution yield | 0.00% |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
BBP fund facts
| Issuer | Virtus |
|---|---|
| Theme | Biotech |
| Assets under management | $127M |
| Expense ratio | 0.77% |
| Number of holdings | 50 |
| Portfolio turnover | 48% |
| Inception | Dec 16, 2014 |
| Exchange | NYSE |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.
BBP top holdings
| Holding | Sector | Weight |
|---|---|---|
| Moderna Inc MRNA | Healthcare | 5.54% |
| Iovance Biotherapeutics Inc IOVA | Healthcare | 4.76% |
| Omeros Corporation OMER | Healthcare | 2.94% |
| Verastem Inc VSTM | Healthcare | 2.51% |
| Precigen Inc PGEN | Healthcare | 2.27% |
| Halozyme Therapeutics Inc HALO | Healthcare | 1.98% |
| Xeris Pharmaceuticals Inc XERS | Healthcare | 1.89% |
| Kiniksa Pharmaceuticals Ltd KNSA | Healthcare | 1.94% |
| Rigel Pharmaceuticals Inc RIGL | Healthcare | 1.96% |
| NantKwest Inc NK | Healthcare | 1.87% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
BBP sector breakdown
| Sector | Weight |
|---|---|
| Healthcare | 100.0% |
By region: North America 95.1%, Asia Emerging 2.0%, United Kingdom 1.5%, Europe Developed 1.4%.
BBP returns and risk
| Year to date | +27.3% |
|---|---|
| 1 year | +40.8% |
| 3 years (annualised) | +27.8% |
| 5 years (annualised) | +15.1% |
| 10 years (annualised) | +11.8% |
| Volatility (3 years) | 20.2% |
| Sharpe ratio (3 years) | 1.13 |
Past returns do not guarantee future results.
BBP: frequently asked questions
What does BBP invest in?
Virtus Biotech ETF invests in a portfolio of securities. Its largest holdings are Moderna Inc (5.5%), Iovance Biotherapeutics Inc (4.8%), Omeros Corporation (2.9%), Verastem Inc (2.5%), Precigen Inc (2.3%).
What is the BBP expense ratio?
0.77% a year: about $77.00 for every $10,000 invested.
What is the BBP dividend yield?
0.00%. ATLAS does not hold the exact distribution dates for ETFs.
Will BBP go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 51%, with a likely range (50%) of $97.60 to $107.83 from $102.35 today. It is a probability, not a prediction.
How has BBP performed?
Year to date +27.3%, one year +40.8%, three years +27.8% a year, five years +15.1% a year. Past returns do not guarantee future results.
Similar ETFs: Biotech
Educational information, not investment advice. Disclaimer